Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
Ilana M BraunKari BohlkeDonald I AbramsHolly AndersonNicholas G ZaorskyLynda G BalneavesDaniel W BowlesPeter Ray ChaiAnuja DamaniArjun GuptaSigrun HallmeyerIshwaria M SubbiahChris TwelvesMark S WallaceEric J RoelandPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use. This guideline provides strategies for open, nonjudgmental communication between clinicians and adults with cancer about the use of cannabis and/or cannabinoids. Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens. Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain. This guideline also highlights the critical need for more cannabis and/or cannabinoid research.Additional information is available at www.asco.org/supportive-care-guidelines.
Keyphrases
- papillary thyroid
- squamous cell
- clinical trial
- palliative care
- healthcare
- public health
- chemotherapy induced
- lymph node metastasis
- type diabetes
- squamous cell carcinoma
- randomized controlled trial
- metabolic syndrome
- childhood cancer
- pain management
- quality improvement
- minimally invasive
- insulin resistance
- combination therapy
- study protocol
- weight loss
- double blind